LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Beckman Research Institute
City of Hope, Estados UnidosPublicaciones en colaboración con investigadores/as de Beckman Research Institute (7)
2024
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
2023
-
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375
-
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721
2022
-
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
JTO Clinical and Research Reports, Vol. 3, Núm. 9
2017
-
Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)
Journal of Clinical Oncology, Vol. 35, Núm. 35, pp. 3924-3933
-
Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)
Journal of Clinical Oncology
2015
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
New England Journal of Medicine, Vol. 373, Núm. 2, pp. 123-135